Comutations at baseline in patients with R/R FLT3mut+ AML*
| Gene subgroup, n (%) . | Gilteritinib (n = 239) . | Salvage chemotherapy (n = 122) . | Total (N = 361) . |
|---|---|---|---|
| DNA methylation/hydroxymethylation | 100 (41.8) | 49 (40.0) | 149 (41.2) |
| Transcription factors/regulators | 64 (26.8) | 31 (25.4) | 95 (26.3) |
| Chromatin–spliceosome–other | 47 (19.7) | 16 (13.1) | 63 (17.4) |
| RTK-Ras signaling | 20 (8.4) | 8 (6.6) | 28 (7.8) |
| TP53-aneuploidy | 7 (2.9) | 6 (4.9) | 13 (3.6) |
| NPM1 | 115 (48.1) | 58 (47.5) | 173 (47.9) |
| DNMT3A | 75 (31.4) | 40 (32.8) | 115 (31.9) |
| DNMT3A/NPM1 | 55 (23.0) | 31 (25.4) | 86 (23.8) |
| WT1 | 45 (18.8) | 20 (16.4) | 65 (18.0) |
| IDH1/IDH2 | 38 (15.9) | 18 (14.8) | 56 (15.5) |
| Gene subgroup, n (%) . | Gilteritinib (n = 239) . | Salvage chemotherapy (n = 122) . | Total (N = 361) . |
|---|---|---|---|
| DNA methylation/hydroxymethylation | 100 (41.8) | 49 (40.0) | 149 (41.2) |
| Transcription factors/regulators | 64 (26.8) | 31 (25.4) | 95 (26.3) |
| Chromatin–spliceosome–other | 47 (19.7) | 16 (13.1) | 63 (17.4) |
| RTK-Ras signaling | 20 (8.4) | 8 (6.6) | 28 (7.8) |
| TP53-aneuploidy | 7 (2.9) | 6 (4.9) | 13 (3.6) |
| NPM1 | 115 (48.1) | 58 (47.5) | 173 (47.9) |
| DNMT3A | 75 (31.4) | 40 (32.8) | 115 (31.9) |
| DNMT3A/NPM1 | 55 (23.0) | 31 (25.4) | 86 (23.8) |
| WT1 | 45 (18.8) | 20 (16.4) | 65 (18.0) |
| IDH1/IDH2 | 38 (15.9) | 18 (14.8) | 56 (15.5) |
mut+, mutated.
Some patients had mutations in more than one gene category.